MLTX Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MoonLake Immunotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.99 |
| 52 Week High | US$64.98 |
| 52 Week Low | US$37.55 |
| Beta | 1.31 |
| 1 Month Change | -13.96% |
| 3 Month Change | -0.88% |
| 1 Year Change | -16.76% |
| 3 Year Change | 365.49% |
| 5 Year Change | n/a |
| Change since IPO | 338.42% |
Recent News & Updates
Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?
Jan 20
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate
Dec 16MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold
Oct 13MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27Recent updates
Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?
Jan 20We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate
Dec 16MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold
Oct 13MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Shareholder Returns
| MLTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | 1.8% | -0.8% |
| 1Y | -16.8% | -2.1% | 22.7% |
Return vs Industry: MLTX underperformed the US Biotechs industry which returned -2.1% over the past year.
Return vs Market: MLTX underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| MLTX volatility | |
|---|---|
| MLTX Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MLTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MLTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 50 | Jorge da Silva | www.moonlaketx.com |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics Fundamentals Summary
| MLTX fundamental statistics | |
|---|---|
| Market cap | US$2.90b |
| Earnings (TTM) | -US$80.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-35.9x
P/E RatioIs MLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$80.77m |
| Earnings | -US$80.77m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 05:07 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MoonLake Immunotherapeutics is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandru Cogut | Bryan Garnier & Co |
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |